Ripasudil

Phase 3Small molecule

Ripasudil is one of 33 small molecule programs targeting Fuchs endothelial corneal dystrophy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fuchs Endothelial Corneal DystrophyActive, not recruiting

CataractActive, not recruiting

Fuchs Endothelial Corneal DystrophyPhase 3

Active, not recruiting

CataractPhase 3

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Pred Forte

Novartis

Phase 3

6 2

Bayer Aspirin

Bayer

Phase 3

1 3

Lotemax

BBausch & Lomb Incorporated

Phase 3

7 4

Toradol

JJavelin Pharmaceuticals

Phase 3

4 5

Avastin

BBio-Thera Solutions

Phase 3

1 6

KPI-121

KKala Pharmaceuticals, Inc.

Phase 3

1 7

Ripasudil

KKowa Research Institute, Inc.

Phase 3

2 8

Zolymbus

AbbVie

Preclinical

—9

Neurontin

VViatris Specialty LLC

Preclinical

3 10

Ceftin

PPhiladelphia Eye Associates

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Trial

NCT05289661

Q4 2028

Phase 3Recruiting

Trial

NCT05275972

Clinical

Trials by Indication[1]

Trial2 trials

Descemet Endothelial Thickness Comparison Trial II

Recruiting·SStanford University·Phase 3·NCT05275972·60 enrolled

Descemet Endothelial Thickness Comparison Trial I

Active, not recruiting·SStanford University·Phase 3·NCT05289661·160 enrolled

Fuchs endothelial corneal dystrophy2 trials

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

Completed·KKowa Research Institute, Inc.·Phase 3·NCT05795699·107 enrolled

A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

Completed·KKowa Research Institute, Inc.·Phase 3·NCT05826353·110 enrolled

Cataract2 trials

A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery

Completed·KKowa Research Institute, Inc.·Phase 3·NCT05528172·331 enrolled

The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery

Recruiting·SSingapore Eye Research Institute·Phase 3·NCT06048380·120 enrolled

ESS1 trial

Study to Assess Safety and Tolerability of Multiple Doses of EO2002

Recruiting·AAsociación para Evitar la Ceguera en México·Phase 1·NCT05636579·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Ripasudil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ripasudil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ripasudil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kowa Research Institute, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKowa Research Institute, Inc.

Ripasudil

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Trials by Indication[1]

Trial2 trials

Fuchs endothelial corneal dystrophy2 trials

Cataract2 trials

ESS1 trial

References

Drug Info

Quick Facts

Related News